Global Health, McMaster University, Hamilton, Ontario, Canada.
Physical and environmenal science, University of Toronto, Toronto, Ontario, Canada.
BMJ Open. 2023 Mar 17;13(3):e062734. doi: 10.1136/bmjopen-2022-062734.
The COVID-19 pandemic has highlighted insufficiencies and gaps within healthcare systems globally. In most countries, including high-income countries, healthcare facilities were over-run and occupied with too few resources beyond capacity. We carried out a systematic review with a primary aim to identify the influence of the COVID-19 pandemic on the presentation and treatment of stroke globally in populations≥65 years of age.
A systematic review was completed. In total, 38 papers were included following full-text screening.
PubMed, MEDLINE and Embase.
Eligible studies included observational and real-world evidence publications with a population who have experienced stroke treatment during the COVID-19 pandemic. Exclusion criteria included studies comparing the effect of the COVID-19 infection on stroke treatment and outcomes.
Primary outcome measures extracted were the number of admissions, treatment times and patient outcome. Secondary outcomes were severity on admission, population risk factors and destination on discharge. No meta-analysis was performed.
This review demonstrated that 84% of studies reported decreased admissions rates during the COVID-19 pandemic. However, among those admitted, on average, had higher severity of stroke. Additionally, in-hospital stroke treatment pathways were affected by the implementation of COVID-19 protocols, which resulted in increased treatment times in 60% of studies and increased in-hospital mortality in 82% of studies by 100% on average. The prevalence of stroke subtype (ischaemic or haemorrhagic) and primary treatment methods (thrombectomy or thrombolysis) did not vary due to the COVID-19 pandemic.
During the COVID-19 pandemic, many populations hesitated to seek medical attention, decreasing hospital admissions for less severe strokes and increasing hospitalisation of more severe cases and mortality. The effect of the pandemic on society and healthcare systems needs to be addressed to improve stroke treatment pathways and prepare for potential future epidemics.
CRD42021248564.
新冠疫情凸显了全球医疗体系的不足和差距。在大多数国家,包括高收入国家,医疗设施都被挤爆,资源匮乏,不堪重负。我们进行了一项系统评价,主要目的是确定新冠疫情对全球≥65 岁人群中卒中的表现和治疗的影响。
系统评价。经过全文筛选,共纳入 38 篇论文。
PubMed、MEDLINE 和 Embase。
符合条件的研究包括观察性和真实世界证据出版物,其人群在新冠疫情期间经历过卒中治疗。排除标准包括比较新冠感染对卒中治疗和结局影响的研究。
提取的主要结果测量指标为入院人数、治疗时间和患者结局。次要结果为入院时的严重程度、人群风险因素和出院去向。未进行荟萃分析。
本综述表明,84%的研究报告称新冠疫情期间入院率下降。然而,在入院的患者中,卒中的严重程度平均更高。此外,由于实施了新冠协议,卒中院内治疗路径受到影响,60%的研究中治疗时间延长,82%的研究中院内死亡率平均增加 100%。卒中亚型(缺血性或出血性)和主要治疗方法(血栓切除术或溶栓)的流行率不因新冠疫情而改变。
在新冠疫情期间,许多人犹豫不决,不愿寻求医疗帮助,导致轻度卒中的入院人数减少,而严重病例的住院人数和死亡率增加。需要解决疫情对社会和医疗体系的影响,以改善卒中治疗路径并为潜在的未来疫情做好准备。
CRD42021248564。